Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
Seven Talking Points At ASH 2019
The tireless pace of change in hemato-oncology was showcased in Orlando.
J&J’s Darzalex Scores Again In Frontline Myeloma
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
UniQure Aiming To Be First With Hemophilia B Gene Therapy
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Astellas To Pay $3bn For Gene Therapy Company Audentes
Japanese company joins the ranks of big pharma buying up gene therapy pioneers